A detailed history of Uss Investment Management LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Uss Investment Management LTD holds 48,396 shares of VRTX stock, worth $24.3 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
48,396
Previous 47,418 2.06%
Holding current value
$24.3 Million
Previous $19.8 Million 14.44%
% of portfolio
0.18%
Previous 0.17%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $384,168 - $474,848
978 Added 2.06%
48,396 $22.7 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $590,742 - $646,369
1,449 Added 3.15%
47,418 $19.8 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $2.27 Million - $2.72 Million
-6,620 Reduced 12.59%
45,969 $18.7 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $367,601 - $393,994
1,087 Added 2.11%
52,589 $18.3 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $177,018 - $198,125
563 Added 1.11%
51,502 $18.1 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $743,478 - $848,137
2,625 Added 5.43%
50,939 $16 Million
Q3 2022

Nov 08, 2022

SELL
$273.83 - $305.53 $5.15 Million - $5.75 Million
-18,809 Reduced 28.02%
48,314 $14 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $751,167 - $935,282
-3,197 Reduced 4.55%
67,123 $18.9 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $1.31 Million - $1.54 Million
5,908 Added 9.17%
70,320 $18.4 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $7.51 Million - $8.4 Million
41,375 Added 179.6%
64,412 $11.7 Million
Q3 2020

Oct 30, 2020

BUY
$255.65 - $303.1 $225,994 - $267,940
884 Added 3.99%
23,037 $6.26 Million
Q2 2020

Aug 11, 2020

BUY
$225.48 - $295.8 $5 Million - $6.55 Million
22,153 New
22,153 $6.44 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Uss Investment Management LTD Portfolio

Follow Uss Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Uss Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Uss Investment Management LTD with notifications on news.